NTHI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NT

Mkt Cap

$77.8M

Volume

95.19K

Next Earnings

November 13th

Loading chart

NT

NTHINeOnc Technologies Holdings, Inc. Common Stock

NTHI

Pay with—

Available Balance0.00

NT

Mkt Cap

$79.2M

Volume

95.19K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu DhabiNeOnc Technologies announced early clinical improvements in a critically ill three-year-old boy treated with investigational intranasal NEO100 through its Compassionate Care program in Abu Dhabi. The patient is now breathing independently without ventilator support and showing renewed leg movement. The company emphasized these observations involve a single patient and do not establish efficacy or predict outcomes in other patients.GlobeNewswire Inc. · Oct 16, 2026

NeOnc Technologies Appoints Ali Alabedin to Its Board of DirectorsNeOnc Technologies announced the appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026. The appointment strengthens financial governance as NeOnc advances its clinical programs and expands operations in Abu Dhabi. The Department of Health – Abu Dhabi has granted IND authorization for NEO212, supporting Phase 2 development in the UAE.GlobeNewswire Inc. · Oct 14, 2026

NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next FrontierNeOnc Technologies (NASDAQ: NTHI) is advancing NEO100, an intranasal-delivered therapy for IDH1-mutant gliomas, following promising Phase 2a results showing 48.9% six-month progression-free survival versus a 20% benchmark with no major toxicities. The company plans to seek FDA guidance on a registrational pathway, with potential broader implications for nose-to-brain drug delivery technology.GlobeNewswire Inc. · Sep 22, 2026

NeOnc Charting New Nasal Route to Treating Brain CancerNeOnc Technologies (NASDAQ: NTHI) reported Phase 2a results for NEO100, an intranasal formulation of perillyl alcohol for recurrent high-grade glioma. The 24-patient study showed 48.9% six-month progression-free survival versus a 20% benchmark (p=0.0047), with median overall survival of 26.09 months. The novel nose-to-brain delivery approach aims to overcome blood-brain barrier challenges. While results are encouraging, the small sample size and open-label design warrant confirmation in larger randomized trials before regulatory approval.GlobeNewswire Inc. · Sep 21, 2026

NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDANeOnc Technologies (NASDAQ: NTHI) executives have purchased approximately $629,000 in company shares following positive Phase 2a results for its brain-cancer therapy NEO100. The Phase 2a study met its primary endpoint with 48.9% six-month progression-free survival compared to a 20% benchmark, with a p-value of 0.0047. The company also announced a $15 million registered direct offering and has a second program, NEO212, advancing toward Phase 2 trials.GlobeNewswire Inc. · Sep 16, 2026

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data ReadoutNeOnc Technologies announced Q2 2026 financial results with increased R&D spending of $2.6M (up from $0.7M YoY) to support clinical development. The company completed topline analysis of its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma with results to be presented August 12, 2026. NeOnc secured UAE IND approvals for both NEO100 and NEO212 programs and appointed Nasim Shomali to its Board. The company reported a net loss of $14.2M for Q2 2026 with $2.0M in cash and an undrawn $10M credit line.GlobeNewswire Inc. · Aug 10, 2026

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain TumorsNeOnc Technologies revealed preclinical research demonstrating that ultrasound can enhance the therapeutic potency of NEO100 for treating primary and metastatic brain tumors, using an AI-driven 3D-bioprinted methodology.GlobeNewswire Inc. · Dec 1, 2025

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use ProgramNeOnc Technologies will host an investor conference call to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial, focusing on intranasal delivery of NEO100 for treating recurrent high-grade malignant glioma.GlobeNewswire Inc. · Nov 7, 2025

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of DirectorsNeOnc Technologies' subsidiary NuroMENA signed a Master Services Agreement with IROS, part of M42, to accelerate clinical cancer therapy development in the Middle East. The company also expanded its NuroMENA board by adding members from Quazar Investment.GlobeNewswire Inc. · Oct 9, 2025

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory BoardNeOnc Technologies has appointed renowned neuro-oncologist Dr. Henry S. Friedman to its scientific advisory board, strengthening its expertise in developing therapies for central nervous system cancers.GlobeNewswire Inc. · Sep 29, 2025

to start trading

NT

NTHINeOnc Technologies Holdings, Inc. Common Stock

NTHI

Pay with—

Available Balance0.00

Your PositionYou don't own any NTHI yet.

Related Tickers

Earnings